Free Trial

Perspective Therapeutics (CATX) Competitors

Perspective Therapeutics logo
$2.51 +0.05 (+2.03%)
Closing price 04:00 PM Eastern
Extended Trading
$2.58 +0.08 (+2.99%)
As of 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CATX vs. EMBC, IRMD, CBLL, BBNX, AVNS, BFLY, KIDS, RXST, BVS, and AXGN

Should you be buying Perspective Therapeutics stock or one of its competitors? The main competitors of Perspective Therapeutics include Embecta (EMBC), Iradimed (IRMD), CeriBell (CBLL), Beta Bionics (BBNX), Avanos Medical (AVNS), Butterfly Network (BFLY), OrthoPediatrics (KIDS), RxSight (RXST), Bioventus (BVS), and AxoGen (AXGN). These companies are all part of the "medical equipment" industry.

Perspective Therapeutics vs.

Perspective Therapeutics (NYSE:CATX) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Perspective Therapeutics currently has a consensus price target of $12.50, indicating a potential upside of 398.01%. Embecta has a consensus price target of $20.33, indicating a potential upside of 93.47%. Given Perspective Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Perspective Therapeutics is more favorable than Embecta.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Perspective Therapeutics
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
3 Strong Buy rating(s)
3.18
Embecta
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

Embecta has a net margin of 5.25% compared to Perspective Therapeutics' net margin of -4,096.66%. Embecta's return on equity of -19.22% beat Perspective Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Perspective Therapeutics-4,096.66% -27.40% -23.16%
Embecta 5.25%-19.22%11.92%

Perspective Therapeutics received 33 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 97.22% of users gave Perspective Therapeutics an outperform vote while only 10.53% of users gave Embecta an outperform vote.

CompanyUnderperformOutperform
Perspective TherapeuticsOutperform Votes
35
97.22%
Underperform Votes
1
2.78%
EmbectaOutperform Votes
2
10.53%
Underperform Votes
17
89.47%

Perspective Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Embecta has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500.

54.7% of Perspective Therapeutics shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 3.7% of Perspective Therapeutics shares are owned by insiders. Comparatively, 0.4% of Embecta shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Embecta has higher revenue and earnings than Perspective Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perspective Therapeutics$1.43M130.29-$46.51MN/AN/A
Embecta$1.08B0.57$78.30M$0.9011.68

In the previous week, Perspective Therapeutics had 14 more articles in the media than Embecta. MarketBeat recorded 17 mentions for Perspective Therapeutics and 3 mentions for Embecta. Embecta's average media sentiment score of 1.03 beat Perspective Therapeutics' score of 0.90 indicating that Embecta is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Perspective Therapeutics
7 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Embecta
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Perspective Therapeutics beats Embecta on 9 of the 17 factors compared between the two stocks.

Get Perspective Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CATX vs. The Competition

MetricPerspective TherapeuticsSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$186.31M$4.43B$5.33B$19.30B
Dividend YieldN/A43.63%5.21%3.84%
P/E RatioN/A29.0826.7134.53
Price / Sales130.2966.76386.1334.83
Price / CashN/A51.0838.2517.51
Price / Book0.946.196.774.69
Net Income-$46.51M$67.60M$3.23B$1.02B
7 Day Performance4.15%-0.63%1.80%-1.74%
1 Month Performance17.29%17.91%11.10%7.50%
1 Year Performance-83.15%21.16%17.11%4.15%

Perspective Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CATX
Perspective Therapeutics
3.4274 of 5 stars
$2.51
+2.0%
$12.50
+398.0%
-84.4%$186.31M$1.43M0.0070News Coverage
Analyst Revision
EMBC
Embecta
4.1536 of 5 stars
$12.41
+3.7%
$20.33
+63.8%
-9.8%$721.44M$1.11B12.411,900Positive News
Analyst Upgrade
High Trading Volume
IRMD
Iradimed
4.8919 of 5 stars
$52.57
+1.4%
$72.00
+37.0%
+20.6%$668.43M$75.15M35.05110Positive News
CBLL
CeriBell
2.7292 of 5 stars
$17.16
+7.5%
$32.50
+89.4%
N/A$618.36M$65.44M0.00N/APositive News
Insider Trade
Gap Up
BBNX
Beta Bionics
N/A$14.18
+1.6%
$24.83
+75.1%
N/A$614.79M$65.12M0.00294Gap Up
AVNS
Avanos Medical
2.6733 of 5 stars
$13.08
+3.4%
N/A-37.4%$601.81M$689.20M38.484,040Positive News
BFLY
Butterfly Network
2.6244 of 5 stars
$2.35
+5.2%
$4.00
+70.6%
+99.5%$579.89M$85.63M-5.10460Gap Up
KIDS
OrthoPediatrics
4.6056 of 5 stars
$23.27
+5.6%
$35.83
+54.0%
-33.7%$565.16M$204.73M-18.92200Gap Up
RXST
RxSight
3.0021 of 5 stars
$13.75
+5.3%
$37.60
+173.5%
-74.3%$558.76M$148.31M-16.57220Positive News
Analyst Upgrade
High Trading Volume
BVS
Bioventus
3.1649 of 5 stars
$6.74
+0.9%
$14.33
+112.7%
+5.5%$552.30M$567.70M-11.051,200Gap Up
AXGN
AxoGen
3.4059 of 5 stars
$11.39
+0.3%
$22.60
+98.4%
+87.2%$518.64M$187.34M-35.59450

Related Companies and Tools


This page (NYSE:CATX) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners